Bristol inks $2.4B deal for Medarex

Bristol-Myers Squibb agreed to buy Medarex for about $2.4 billion to double its pipeline of experimental biological drugs, including one nearing U.S. approval for skin cancer. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.